KRAS-mutant NSCLC is a heterogeneous disease of molecular subgroups bearing co-occurring genomic alterations falling mainly into three divisions comprising TP53, STK11/liver kinase B1 (LKB1) and CDKN2A/B alterations with different impacts on prognosis [30]. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.